Tissue factor in tumour progression

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 1, 2009, Pages 71-83

  Rak, Janusz ^a   Milsom, Chloe ^b   Magnus, Nathalie ^c   Yu, Joanne ^d  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

angiogenesis; cancer; cancer stem cells; coagulation; oncogenes; tissue factor

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; RETINOIC ACID RECEPTOR ALPHA; THROMBIN; THROMBOPLASTIN;

BLADDER CANCER; BLOOD CLOTTING; BRAIN CANCER; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; COLON CANCER; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LEUKEMIA; LIVER CANCER; LUNG CANCER; LUNG EMBOLISM; MALIGNANT TRANSFORMATION; MELANOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM;

DISEASE PROGRESSION; HUMANS; NEOPLASMS; THROMBOPLASTIN;

EID: 61649107664     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.12.008     Document Type: Review

References (133)

1. Folkman J., and Kalluri R. Tumor angiogenesis. In: Kufe D.W., Pollock R.E., and Weichselbaum R.R. (Eds). Cancer medicine (2003), BC Decker Inc, Hamilton, London 161-194
2. Rak J., and Kerbel R.S. Oncogenes and tumor angiogenesis. In: Rak J. (Ed). Oncogene-directed therapies (2003), Humana Press, Totowa 171-218
3. Tehrani M., Friedman T.M., Olson J.J., et al. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol 18 (2008) 164-171
4. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 (2008) 2039-2049
5. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
6. Italiano Jr. J.E., Richardson J.L., Patel-Hett S., et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111 (2008) 1227-1233
7. Yu J.L., May L., Lhotak V., et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105 (2005) 1734-1741
8. Dolo V., D'Ascenzo S., Giusti I., et al. Shedding of membrane vesicles by tumor and endothelial cells. Ital J Anat Embryol 110 (2005) 127-133
9. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 55 (2006) 808-818
10. Gesierich S., Berezovskiy I., Ryschich E., et al. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res 66 (2006) 7083-7094
11. Rafii S., Lyden D., Benezra R., et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2 (2002) 826-835
12. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7 (2001) 575-583
13. Shojaei F., Singh M., Thompson J.D., et al. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA 105 (2008) 2640-2645
14. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
15. Rak J., Filmus J., and Kerbel R.S. Reciprocal paracrine interactions between tumor cells and endothelial cells. The "angiogenesis progression" hypothesis. Eur J Cancer 32A (1996) 2438-2450
16. Skobe M., Rockwell P., Goldstein N., et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3 (1997) 1222-1227
17. Bajou K., Noel A., Gerard R.D., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4 (1998) 923-928
18. Ferrara N., Hillan K.J., Gerber H.P., et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
19. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
20. Fernando N.H., and Hurwitz H.I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9 Suppl. 1 (2004) 11-18
21. Sandler A., and Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12 (2006) 4421-4425
22. Pettersson A., Nagy J.A., Brown L.F., et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 80 (2000) 99-115
23. McDonald D.M., and Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat Med 9 (2003) 713-725
24. St. Croix B., Rago C., Velculescu V., et al. Genes expressed in human tumor endothelium. Science 289 (2000) 1197-1202
25. Dvorak F.H., and Rickles F.R. Malignancy and hemostasis. In: Coleman R.B., Marder V.J., Clowes A.W., George J.N., and Goldhaber S.Z. (Eds). Hemostasis and thrombosis: basic principles and clinical practice (2006), Lippincott Company Williams & Wilkins, Philadelphia 851-873
26. Rickles F.R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 35 (2006) 103-110
27. Klement H., St C.B., Milsom C., et al. Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am J Pathol 171 (2007) 1342-1351
28. Falanga A., Barbui T., and Rickles F.R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 34 (2008) 204-210
29. Levine M.N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318 (1988) 404-407
30. Zacharski L.R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin Thromb Hemost 29 (2003) 239-246
31. Buller H.R., van Doormaal F.F., van Sluis G.L., et al. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 5 Suppl. 1 (2007) 246-254
32. Tesselaar M.E., Romijn F.P., Van Der Linden I.K., et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 5 (2007) 520-527
33. Zwicker J.I., Furie B.C., and Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 62 (2007) 126-136
34. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 31 (2005) 104-110
35. Rickles F.R., Patierno S., and Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 124 (2003) 58S-68
36. Petralia G.A., Lemoine N.R., and Kakkar A.K. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2 (2005) 356-363
37. Lee A.Y., Rickles F.R., Julian J.A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005) 2123-2129
38. Kakkar A.K., Levine M.N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22 (2004) 1944-1948
39. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271
40. Rak J., Yu J.L., Luyendyk J., et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 66 (2006) 10643-10646
41. Kuenen B.C., Levi M., Meijers J.C., et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 22 (2002) 1500-1505
42. Boccaccio C., Sabatino G., Medico E., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434 (2005) 396-400
43. Tallman M.S., Lefebvre P., Baine R.M., et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2 (2004) 1341-1350
44. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24 (2004) 1015-1022
45. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 407 (2000) 258-264
46. Ruf W. Redundant signaling of tissue factor and thrombin in cancer progression?. J Thromb Haemost 5 (2007) 1584-1587
47. Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 25 (2005) 2273-2281
48. Milsom C., Yu J., May L., et al. Diverse roles of tissue factor-expressing cells in tumor progression. Semin Thromb Hemost 34 (2008) 170-181
49. Contrino J., Hair G., Kreutzer D.L., et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2 (1996) 209-215
50. Rak J., Milsom C., and Yu J. Tissue factor in cancer. Curr Opin Hematol 15 (2008) 522-528
51. Croce C.M. Oncogenes and cancer. N Engl J Med 358 (2008) 502-511
52. Rak J., and Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 19 (2000) 93-96
53. Rong Y., Post D.E., Pieper R.O., et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 65 (2005) 1406-1413
54. Yu J.L., and Rak J.W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2 (2004) 2065-2067
55. Yu J., May L., Milsom C., et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 28 (2008) 1975-1981
56. Al-Nedawi K., Meehan B., Micallef J., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10 (2008) 619-624
57. Bogdanov V.Y., Balasubramanian V., Hathcock J., et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9 (2003) 458-462
58. Hobbs J.E., Zakarija A., Cundiff D.L., et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 120 Suppl. 2 (2007) S13-S21
59. Chand H.S., Ness S.A., and Kisiel W. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. Int J Cancer 118 (2006) 1713-1720
60. Szotowski B., Antoniak S., and Rauch U. Alternatively spliced tissue factor: a previously unknown piece in the puzzle of hemostasis. Trends Cardiovasc Med 16 (2006) 177-182
61. Mackman N. Alternatively spliced tissue factor - one cut too many?. Thromb Haemost 97 (2007) 5-8
62. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15 (2003) 740-746
63. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
64. Palumbo J.S., Talmage K.E., Massari J.V., et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110 (2007) 133-141
65. Francis J.L., and Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 28 (2002) 29-38
66. Mueller B.M., Reisfeld R.A., Edgington T.S., et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89 (1992) 11832-11836
67. Milsom C., Yu J., Mackman N., et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 68 (2008) 10068-10076
68. Mani S.A., Guo W., Liao M.J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008) 704-715
69. Milsom C., Anderson G.M., Weitz J.I., et al. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 5 (2007) 2550-2552
70. Vrana J.A., Stang M.T., Grande J.P., et al. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 56 (1996) 5063-5070
71. Lwaleed B.A., Bass P.S., and Cooper A.J. The biology and tumour-related properties of monocyte tissue factor. J Pathol 193 (2001) 3-12
72. Belting M., Dorrell M.I., Sandgren S., et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10 (2004) 502-509
73. Ngo C.V., Manning C.A., McCabe F., et al. Combination antibody therapy targeting both xenograft- and host-derived tissue factor leads to potent tumor inhibition. Proc Am Assoc Cancer Res 46 (2005)
74. Mechtcheriakova D., Wlachos A., Holzmuller H., et al. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 93 (1999) 3811-3823
75. Zhang Y., Deng Y., Luther T., et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94 (1994) 1320-1327
76. Hembrough T.A., Swartz G.M., Papathanassiu A., et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 63 (2003) 2997-3000
77. Abe K., Shoji M., Chen J., et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 96 (1999) 8663-8668
78. Bromberg M.E., Sundaram R., Homer R.J., et al. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 82 (1999) 88-92
79. Ngo C.V., Picha K., McCabe F., et al. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer 120 (2007) 1261-1267
80. Versteeg H.H., Schaffner F., Kerver M., et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 111 (2008) 190-199
81. Wang X., Wang M., Amarzguioui M., et al. Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer 112 (2004) 994-1002
82. Hu Z., and Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci U S A 98 (2001) 12180-12185
83. Toomey J.R., Kratzer K.E., Lasky N.M., et al. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA 94 (1997) 6922-6926
84. Lazarus R.A., Olivero A.G., Eigenbrot C., et al. Inhibitors of tissue factor. Factor VIIa for anticoagulant therapy. Curr Med Chem 11 (2004) 2275-2290
85. Viloria-Petit A., Miquerol L., Yu J.L., et al. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 22 (2003) 4091-4102
86. Koizume S., Jin M.S., Miyagi E., et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 66 (2006) 9453-9460
87. Huang X., Molema G., King S., et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275 (1997) 547-550
88. Klerk C.P., Smorenburg S.M., Otten H.M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135
89. Lwaleed B.A., Francis J.L., and Chisholm M. Urinary tissue factor levels in patients with bladder and prostate cancer. Eur J Surg Oncol 26 (2000) 44-49
90. Forster Y., Meye A., Albrecht S., et al. Tissue specific expression and serum levels of human tissue factor in patients with urological cancer. Cancer Lett 193 (2003) 65-73
91. Patry G., Hovington H., Larue H., et al. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. Int J Cancer 122 (2008) 1592-1597
92. Takano S., Tsuboi K., Tomono Y., et al. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 82 (2000) 1967-1973
93. Takeshima H., Nishi T., Kuratsu J., et al. Suppression of the tissue factor-dependent coagulation cascade: a contributing factor for the development of intratumoral hemorrhage in glioblastoma. Int J Mol Med 6 (2000) 271-276
94. Hamada K., Kuratsu J., Saitoh Y., et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77 (1996) 1877-1883
95. Guan M., Jin J., Su B., et al. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 35 (2002) 321-325
96. Brat D.J., and Van Meir E.G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84 (2004) 397-405
97. Hron G., Kollars M., Weber H., et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97 (2007) 119-123
98. Altomare D.F., Rotelli M.T., Memeo V., et al. Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma. Tumori 89 (2003) 5-6
99. Nakasaki T., Wada H., Shigemori C., et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 69 (2002) 247-254
100. Seto S., Onodera H., Kaido T., et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 88 (2000) 295-301
101. Shigemori C., Wada H., Matsumoto K., et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 80 (1998) 894-898
102. Kataoka H., Uchino H., Asada Y., et al. Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver. Int J Cancer 72 (1997) 878-884
103. Szczepanski M., Bardadin K., Zawadzki J., et al. Procoagulant activity of gastric, colorectal, and renal cancer is factor VII-dependent. J Cancer Res Clin Oncol 114 (1988) 519-522
104. Yamashita H., Kitayama J., Ishikawa M., et al. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 95 (2007) 324-331
105. Nadir Y., Katz T., Sarig G., et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica 90 (2005) 1549-1556
106. Nakasaki T., Wada H., Watanabe R., et al. Elevated tissue factor levels in leukemic cell homogenate. Clin Appl Thromb Hemost 6 (2000) 14-17
107. Lopez-Pedrera C., Jardi M., del Mar M.M., et al. Tissue factor (TF) and urokinase plasminogen activator receptor (uPAR) and bleeding complications in leukemic patients. Thromb Haemost 77 (1997) 62-70
108. Tanaka M., and Yamanishi H. The expression of tissue factor antigen and activity on the surface of leukemic cells. Leuk Res 17 (1993) 103-111
109. Bauer K.A., Conway E.M., Bach R., et al. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 56 (1989) 425-430
110. Negaard H.F., Iversen P.O., Ostenstad B., et al. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost 99 (2008) 1040-1048
111. Semeraro N., Montemurro P., Giordano P., et al. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma. Thromb Haemost 72 (1994) 54-57
112. Goldin-Lang P., Tran Q.V., Fichtner I., et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 20 (2008) 123-128
113. Rauch U., Antoniak S., Boots M., et al. Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood. Lancet Oncol 6 (2005) 254
114. Del Conde I., Bharwani L.D., Dietzen D.J., et al. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 5 (2007) 70-74
115. Langer F., Spath B., Haubold K., et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol (2008)
116. Sawada M., Miyake S., Ohdama S., et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 79 (1999) 472-477
117. Koomagi R., and Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 79 (1998) 19-22
118. Kageshita T., Funasaka Y., Ichihashi M., et al. Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions. Pigment Cell Res 15 (2002) 212-216
119. Uno K., Homma S., Satoh T., et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 96 (2007) 290-295
120. Han L.Y., Landen Jr. C.N., Kamat A.A., et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 24 (2006) 755-761
121. Zacharski L.R., Memoli V.A., Ornstein D.L., et al. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 85 (1993) 1225-1230
122. Khorana A.A., Ahrendt S.A., Ryan C.K., et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13 (2007) 2870-2875
123. Haas S.L., Jesnowski R., Steiner M., et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 12 (2006) 4843-4849
124. Nitori N., Ino Y., Nakanishi Y., et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 11 (2005) 2531-2539
125. Kakkar A.K., Lemoine N.R., Scully M.F., et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82 (1995) 1101-1104
126. Poon R.T., Lau C.P., Ho J.W., et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9 (2003) 5339-5345
127. Kaushal V., Mukunyadzi P., Siegel E.R., et al. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol 16 (2008) 1-6
128. Babiker A.A., Ekdahl K.N., Nilsson B., et al. Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost 33 (2007) 80-86
129. Langer F., Chun F.K., Amirkhosravi A., et al. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost 97 (2007) 464-470
130. Akashi T., Furuya Y., Ohta S., et al. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 62 (2003) 1078-1082
131. Ohta S., Wada H., Nakazaki T., et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 22 (2002) 2991-2996
132. Abdulkadir S.A., Carvalhal G.F., Kaleem Z., et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 31 (2000) 443-447
133. Milsom C., Yu J., May L., et al. The role of tumour- and host-related tissue factor pools in oncogene-driven tumour progression. Thromb Res 120 Suppl. 2 (2007) S82-S91